Integra Lifesciences Holdings (IART)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$16.72+1.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · IART
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 1,647.7 | 1,635.2 | 1,610.5 | 1,541.6 | 1,557.7 | 1,542.4 | 1,371.9 | 1,517.6 | 1,472.4 | 1,188.2 | 992.1 | 882.7 | 796.7 | 696.8 | 830.9 | 780.1 | 732.1 |
| Cost of Revenues | 783.1 | 803.6 | 728.5 | 656.8 | 587.4 | 597.8 | 520.8 | 564.7 | 571.5 | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | 851.0 | 952.9 | 900.9 | 752.7 | 643.0 | 556.2 | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | 689.0 | 699.7 | 717.0 | 656.6 | 616.3 | 637.4 | 594.5 | 687.6 | 690.7 | 624.1 | 455.6 | 415.8 | 375.5 | 332.2 | 373.1 | 358.1 | 305.1 |
| R&D Expenses | — | — | — | — | — | — | — | — | 78.0 | 63.5 | 58.2 | 50.9 | 43.6 | 42.6 | 51.0 | 51.5 | 48.1 |
| Operating Income | 65.6 | (493.4) | 28.4 | 111.5 | 238.9 | 197.2 | 151.4 | 93.8 | 111.0 | 44.8 | 115.3 | 79.6 | 67.9 | 35.4 | 73.8 | 54.9 | 98.7 |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | 86.3 | 70.6 | 51.4 | 49.6 | 50.4 | 71.6 | 54.0 | 64.7 | 35.0 | 25.8 | 23.5 | 22.0 | 19.7 | 22.2 | 27.6 | 18.4 |
| Interest & Investment Income | 17.7 | 18.5 | 20.0 | 17.2 | 11.9 | 6.7 | 9.3 | 10.8 | 2.8 | 0.3 | 0.0 | 0.0 | 0.2 | 4.9 | 1.2 | 0.5 | 0.2 |
| Net Interest Expenses | — | — | — | 34.2 | 37.7 | 43.7 | 62.3 | 43.2 | 61.9 | 34.8 | 25.8 | 23.5 | 21.8 | 14.8 | 21.0 | 27.2 | 18.1 |
| Asset Writedown | — | — | — | — | — | — | — | — | — | 3.3 | 0.0 | 0.4 | 0.8 | 0.3 | — | — | — |
| EBT, Incl. Unusual Items | (0.2) | (563.5) | (18.2) | 81.1 | 213.9 | 214.7 | 93.5 | 60.1 | 57.4 | 11.4 | 90.4 | 60.7 | 45.6 | 18.8 | 52.0 | 28.5 | 82.1 |
| Income Tax Expense | 7.1 | (47.0) | (11.3) | 13.3 | 33.3 | 45.6 | (40.4) | 9.9 | (3.4) | (53.4) | 15.8 | 53.8 | 9.3 | (3.2) | 10.8 | 0.5 | 16.4 |
| Net Income | |||||||||||||||||
| Net Income | (7.6) | (516.5) | (6.9) | 67.7 | 180.6 | 169.1 | 133.9 | 50.2 | 60.8 | 64.7 | 74.6 | (3.5) | 34.0 | (21.1) | 41.2 | 28.0 | 65.7 |
| Per Share | |||||||||||||||||
| Basic EPS | (0.10) | (6.74) | (0.09) | 0.85 | 2.18 | 2.00 | 1.58 | 0.59 | 0.73 | 0.84 | 1.00 | (0.05) | 0.52 | (0.74) | 1.46 | 0.97 | 2.21 |
| Diluted EPS | (0.10) | (6.74) | (0.09) | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | (0.05) | 0.52 | (0.74) | 1.44 | 0.95 | 2.17 |
| Revenue per Share | 21.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 77.3 | 76.7 | 77.0 | 80.1 | 83.0 | 84.7 | 84.7 | 85.6 | 82.9 | 76.9 | 74.4 | 69.0 | 64.9 | 28.4 | 28.2 | 29.0 | 29.5 |
| Diluted Weighted Avg Shares | 78.2 | 76.7 | 77.0 | 80.3 | 83.5 | 85.5 | 85.2 | 86.5 | 84.0 | 79.1 | 79.2 | 71.4 | 65.9 | 28.8 | 28.5 | 29.5 | 30.1 |
| Supplemental | |||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | 203.2 | 221.7 | 133.7 | 188.0 | 138.5 | 114.3 | 66.4 | 126.4 | 105.1 | 137.9 |
| EBIT | 65.6 | (493.4) | 28.4 | 111.5 | 238.9 | 197.2 | 151.4 | 93.8 | 111.0 | 44.8 | 115.3 | 79.6 | 67.9 | 35.4 | 73.8 | 54.9 | 98.7 |
| Effective Tax Rate | -3946.4% | — | — | 16.4% | 15.6% | 21.2% | -43.2% | 16.5% | -5.9% | -468.7% | 17.5% | 88.7% | 20.3% | -17.3% | 20.8% | 1.8% | 20.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.